Image: colourbox.de
In a clinical study involving around 17,600 adults over the age of 45 who are overweight or obese and suffer from cardiovascular disease, the drug reduced the risk of a serious cardiovascular event by 20 percent, the company announced yesterday.
The subjects who did not suffer from diabetes received a dose of 2.4 milligrams of the active ingredient semaglutide once a week. The study ran for a period of five years.
The company Novo Nordisk hopes to be able to free Wegovy from the image of a lifestyle drug with the study results. Wegovy is currently not available in Austria (as in most EU countries), but has been available in Germany for a month.
Source: Nachrichten
